Commerzbank Aktiengesellschaft FI boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 30.7% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 26,549 shares of the biopharmaceutical company’s stock after buying an additional 6,229 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Regeneron Pharmaceuticals were worth $13,039,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in REGN. Korea Investment CORP boosted its position in shares of Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 206 shares in the last quarter. Fisher Asset Management LLC boosted its position in shares of Regeneron Pharmaceuticals by 12.7% in the first quarter. Fisher Asset Management LLC now owns 806 shares of the biopharmaceutical company’s stock valued at $312,000 after buying an additional 91 shares in the last quarter. Canada Pension Plan Investment Board boosted its position in shares of Regeneron Pharmaceuticals by 4,188.7% in the first quarter. Canada Pension Plan Investment Board now owns 41,257 shares of the biopharmaceutical company’s stock valued at $15,988,000 after buying an additional 40,295 shares in the last quarter. ING Groep NV purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at about $4,747,000. Finally, State Treasurer State of Michigan boosted its position in shares of Regeneron Pharmaceuticals by 0.8% in the first quarter. State Treasurer State of Michigan now owns 24,944 shares of the biopharmaceutical company’s stock valued at $9,666,000 after buying an additional 200 shares in the last quarter. 67.96% of the stock is currently owned by institutional investors.

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) traded up 1.43% on Friday, reaching $504.00. 699,890 shares of the company traded hands. The firm has a 50-day moving average of $486.42 and a 200-day moving average of $439.67. Regeneron Pharmaceuticals, Inc. has a 52-week low of $325.35 and a 52-week high of $543.55. The company has a market capitalization of $53.44 billion, a PE ratio of 50.56 and a beta of 1.64.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.67 by $1.50. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The business had revenue of $1.47 billion during the quarter, compared to analyst estimates of $1.36 billion. During the same quarter last year, the company posted $2.82 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 21.2% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post $14.85 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This news story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this news story on another domain, it was stolen and republished in violation of international copyright and trademark laws. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/02/commerzbank-aktiengesellschaft-fi-purchases-6229-shares-of-regeneron-pharmaceuticals-inc-regn.html.

Several equities analysts have issued reports on REGN shares. BMO Capital Markets reissued a “hold” rating and issued a $421.00 price objective (up from $412.00) on shares of Regeneron Pharmaceuticals in a research note on Friday, May 5th. Cowen and Company reissued a “hold” rating and issued a $380.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, May 5th. Canaccord Genuity raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and boosted their price objective for the company from $375.00 to $484.00 in a research note on Friday, May 5th. UBS AG set a $489.00 price objective on shares of Regeneron Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, May 5th. Finally, Vetr cut shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating and set a $408.86 price objective on the stock. in a research note on Monday, May 8th. Two investment analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $495.59.

In related news, SVP Robert E. Landry sold 427 shares of the stock in a transaction on Thursday, August 31st. The stock was sold at an average price of $493.43, for a total value of $210,694.61. Following the completion of the transaction, the senior vice president now owns 9,099 shares in the company, valued at approximately $4,489,719.57. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Sanofi purchased 166,415 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The stock was bought at an average price of $480.93 per share, with a total value of $80,033,965.95. The disclosure for this purchase can be found here. Insiders sold a total of 129,405 shares of company stock valued at $61,802,672 in the last quarter. 10.40% of the stock is currently owned by corporate insiders.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Stock Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.